P1611: INSIGHTS INTO FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: FINAL RESULTS FROM THE FIGARO STUDY

Slični predmeti

• Cutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
  od: Sydney Brownlee, i dr.
  Izdano: (2022-11-01)
• Single Center Study Regarding Subucutaneous Immunoglobulins for Secondary Immunodeficiencies in Hematological Malignancies
  od: Daniel Nicolae MURARIU, i dr.
  Izdano: (2024-09-01)
• Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss
  od: Pınar Gür-Çetinkaya, i dr.
  Izdano: (2018-06-01)
• Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry
  od: Sandra Martínez Mercader, i dr.
  Izdano: (2025-02-01)
• A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
  od: Andrea Visentin, i dr.
  Izdano: (2022-12-01)